SARS-CoV-2 (COVID-19) NSP13 (Helicase) Antibody

Infectious Disease, COVID-19

Anti-SARS-CoV-2 (COVID-19) NSP13 (Helicase) antibody (9181) was raised against a peptide corresponding to 19 amino acids near the carboxyl terminus of the SARS-CoV-2 (COVID-19) NSP13 (Helicase) protein.

The immunogen is located in the last 50 amino acids of SARS-CoV-2 (COVID-19) NSP13 (Helicase).

SARS-CoV-2 (COVID-19) NSP13 (Helicase) Antibody is affinity chromatography purified via peptide column.

IgG

SARS-CoV-2 (COVID-19) NSP13 (Helicase) Antibody is supplied in PBS containing 0.02% sodium azide.

SARS-CoV-2 (COVID-19) NSP13 (Helicase) antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.

YP_009725308.1

43740578

ORF1ab

Severe acute respiratory syndrome coronavirus 2

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP13 is a multi-functional protein with a zinc-binding domain in N-terminus displaying RNA and DNA duplex-unwinding activities with 5' to 3' polarity. Activity of Helicase is dependent on magnesium(3, 4).

Hui et al. Int J Infect Dis. 2020; 91:264-266.

Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) NSP13 in COVID-19 Patient Lung
Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) NSP13 antibody (9181, 0.5 μ g/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚ C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 NSP13 protein was observed in macrophage of COVID-19 patient lung, but not in non-COVID-19 patient lung.

Figure 3 ELISA Validation
Antibodies: SARS-CoV-2 (COVID-19) NSP13 (Helicase) Antibody, 9181. A direct ELISA was performed using immunogen peptide (9181P) as coating antigen and the anti-SARS-CoV-2 (COVID-19) NSP13 (Helicase) antibody as the capture antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.3 ng/mL to 1000 ng/mL.